Search
ChatPaper
AI Writing
analysis
Analysis
编组
Open Data
more
More
RankingsMust ReadingJournal&ConferenceAI TRAI HistoryMaster Reading TreeXiaomai's Star TalentsTrajectoryTalentNDI TrackerOpenAI sign Language
VIPCreated with Sketch.

Efficacy and safety of intravenous bevacizumab on severe bleeding associated with hemorrhagic hereditary telangiectasia: A national, randomized multicenter trial.

Sophie Dupuis-Girod,Sophie Rivière,Christian Lavigne,Anne-Emmanuelle Fargeton,Brigitte Gilbert-Dussardier,Vincent Grobost,Vanessa Leguy-Seguin,Hélène Maillard,Shirine Mohamed,Evelyne Decullier,Adeline Roux,Lorraine Bernard,Jean-Christophe Saurin,Nicolas Saroul,Frédéric Faure,Cesar Cartier,Romain Altwegg,Laurent Laccourreye,Frédéric Oberti,Marjolaine Beaudoin, Carole Dhelens,Céline Desvignes,Nicolas Azzopardi,Gilles Paintaud,Ruben Hermann,Thierry Chinet

Journal of internal medicine（2023）

Cited 1|Views19
No score
Abstract
Though the present trial was underpowered, patients with HHT receiving bevacizumab required numerically fewer red blood cell transfusions than those receiving placebo, particularly those with high exposure. This article is protected by copyright. All rights reserved.
More
Translated text
Key words
bevacizumab, hereditary hemorrhagic telangiectasia, rare vascular disease, red blood cell transfusion
AI Read Science
Must-Reading Tree
Example
Generate MRT to find the research sequence of this paper
Chat Paper
Summary is being generated by the instructions you defined